Condensed Consolidated Statement of Stockholders’ Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2023		12,823,665
Beginning balance at Dec. 31, 2023	$ 186,024	$ 0	$ 373,178	$ (187,154)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	1,045		1,045
Common stock issued upon exercise of stock options (in shares)		37,330
Common stock issued upon exercise of stock options	629		629
Net loss	(16,921)			(16,921)
Ending balance (in shares) at Mar. 31, 2024		12,860,995
Ending balance at Mar. 31, 2024	170,777	$ 0	374,852	(204,075)
Beginning balance (in shares) at Dec. 31, 2023		12,823,665
Beginning balance at Dec. 31, 2023	186,024	$ 0	373,178	(187,154)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(55,630)
Ending balance (in shares) at Sep. 30, 2024		13,010,867
Ending balance at Sep. 30, 2024	137,414	$ 0	380,198	(242,784)
Beginning balance (in shares) at Mar. 31, 2024		12,860,995
Beginning balance at Mar. 31, 2024	170,777	$ 0	374,852	(204,075)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	2,314		2,314
Shares issued upon the exercise of pre-funded warrants (in shares)		103,407
Common stock issued upon exercise of stock options (in shares)		24,806
Common stock issued upon exercise of stock options	415		415
Net loss	(18,492)			(18,492)
Ending balance (in shares) at Jun. 30, 2024		12,989,208
Ending balance at Jun. 30, 2024	155,014	$ 0	377,581	(222,567)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	2,474		2,474
Common stock issued upon exercise of stock options (in shares)		21,659
Common stock issued upon exercise of stock options	143		143
Net loss	(20,217)			(20,217)
Ending balance (in shares) at Sep. 30, 2024		13,010,867
Ending balance at Sep. 30, 2024	$ 137,414	$ 0	380,198	(242,784)
Beginning balance (in shares) at Dec. 31, 2024	14,854,725	14,854,725
Beginning balance at Dec. 31, 2024	$ 310,375	$ 0	572,673	(262,298)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	4,048		4,048
Common stock issued upon exercise of stock options (in shares)		1,683
Common stock issued upon exercise of stock options	19		19
Common stock issued upon vesting of restricted stock units (in shares)		73,158
Net loss	(22,647)			(22,647)
Ending balance (in shares) at Mar. 31, 2025		14,929,566
Ending balance at Mar. 31, 2025	$ 291,795	$ 0	576,740	(284,945)
Beginning balance (in shares) at Dec. 31, 2024	14,854,725	14,854,725
Beginning balance at Dec. 31, 2024	$ 310,375	$ 0	572,673	(262,298)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued upon exercise of stock options (in shares)	14,902
Net loss	$ (65,616)
Ending balance (in shares) at Sep. 30, 2025	14,775,285	14,775,285
Ending balance at Sep. 30, 2025	$ 265,540	$ 0	593,454	(327,914)
Beginning balance (in shares) at Mar. 31, 2025		14,929,566
Beginning balance at Mar. 31, 2025	291,795	$ 0	576,740	(284,945)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	3,408		3,408
Exchange of common stock for pre-funded warrants (in shares)		(667,500)
Common stock issued upon exercise of stock options (in shares)		7,198
Common stock issued upon exercise of stock options	68		68
Net loss	(22,016)			(22,016)
Ending balance (in shares) at Jun. 30, 2025		14,269,264
Ending balance at Jun. 30, 2025	273,255	$ 0	580,216	(306,961)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	3,365		3,365
Issuance of common stock in at-the-market offering (in shares)		500,000
Issuance of common stock in at-the-market sales agreement, net of offering costs	9,784		9,784
Common stock issued upon exercise of stock options (in shares)		6,021
Common stock issued upon exercise of stock options	89		89
Net loss	$ (20,953)			(20,953)
Ending balance (in shares) at Sep. 30, 2025	14,775,285	14,775,285
Ending balance at Sep. 30, 2025	$ 265,540	$ 0	$ 593,454	$ (327,914)